VRTX Added to Goldman Sachs Conviction List Amid Modest Overvaluation

Goldman Sachs has added Vertex Pharmaceuticals (VRTX) to its U.S. conviction list for September, a move that underscores the company's strategic positioning in the biotechnology space.

The GF Value™ metric suggests VRTX is trading at $547.65, approximately 4.8% above its intrinsic value estimate of $522.44, indicating modest overvaluation.

VRTX operates as a global biotechnology firm focused on discovering and developing small-molecule drugs targeting serious diseases, with a market capitalization of $138.81 billion.